<![CDATA[FDA Grants Breakthrough Device Designation to Merlin CP-GEP in Early-Stage Melanoma ]]>

RegulatoryapprovedMerlin CP-GEPPositive

AI Analysis

Summary

FDA granted Breakthrough Device Designation to Merlin CP-GEP for early-stage melanoma (T1b/T2a), with the device also gaining NCCN inclusion to help refine sentinel lymph node biopsy decisions based on MERLIN_001 trial data.

Clinical Trial Data

Outcome Details

FDA granted Breakthrough Device Designation; NCCN inclusion

Importance:7/10

Sentiment:

0.85

FDA breakthrough designationmelanomadeviceNCCN inclusionSLNBMERLIN_001 trial

Read the original article

Published by Cancer Network on July 1, 2026 5:00 PM

Read Original